CoChat

Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475.

Kefford, Richard, Ribas, Antoni, Hamid, Omid, Robert, Caroline, Daud, Adil, Wolchok, Jedd D., Joshua, Anthony M., Hodi, F. Stephen, Gangadhar, Tara C., Hersey, Peter, Weber, Jeffrey S., Dronca, Roxana Stefania, Patnaik, Amita, Zarour, Hassane M., Dolled-Filhart, Marisa, Lunceford, Jared, Emancipator, Kenneth, Ebbinghaus, Scot, Kang, Soonmo Peter, Hwu, Wen-Jen · 2014 · Journal of Clinical Oncology
Cited by 89

The DOI matches its Crossref record.

Abstract

3005^ Background: MK-3475 demonstrated antitumor activity and acceptable safety in a phase I MEL cohort. We provide updated efficacy data and correlation with tumor PD-L1 expression. Methods: 135 pts received MK-3475 10 mg/kg Q2W (n = 57), 10 mg/kg Q3W (n = 56), or 2 mg/kg Q3W (n = 22). Response was assessed every 12 wk by RECIST 1.1 by independent central review and by immune-related response criteria (irRC) by investigator. Biopsy was required in the 60 d before MK-3475. Tumor PD-L1 expression was assessed by IHC. A preliminary cutoff of 1% of stained tumor cells defined PD-L1 positivity. Results: As of 10/18/2013, all pts had ≥13 mo follow-up. Median time on treatment was 23 wk (range, 1 dose to 97 wk). In pts with measurable disease, ORR was 41% by RECIST (Table). Objective responses were observed as late as 64 wk, with some conversions to CR seen as late as 72 wk. Median response duration was not reached; responses were ongoing for 87% of responders. Median PFS was 31 wk. Median OS was not reached, and OS rate at 1 y was 81%. Tumor PD-L1 expression was evaluable in 71 pts with measurable disease and ≥1 tumor evaluation (77% PD-L1+). Of these pts, PD-L1 expression was associated with improved ORR by RECIST (51% vs 6%, P = .0012 [Fisher’s exact]) and PFS (median 12 vs 3 mo, HR 0.31, 95% CI 0.16-0.61, P = .0004 [log-rank]). 1-y OS rate was 84% in PD-L1+ and 69% in PD-L1– pts (P = .2146 [log-rank]). There were no treatment-related deaths; 14% of pts experienced drug-related grade 3/4 AEs. Conclusions: MK-3475 induces durable responses and favorable 1-y OS with acceptable safety in MEL. Although tumor PD-L1 positivity was associated with improved ORR and PFS, antitumor activity was also observed in pts with low baseline PD-L1 expression. These preliminary data require confirmation. Clinical trial information: NCT01295827. RECIST 1.1 irRC 2 Q3W 10 Q3W 10 Q2W Total 2 Q3W 10 Q3W 10 Q2W Total ORR, % (95% CI) 45 (23-69) 31 (18-47) 49 (35-63) 41 (32-51) 32 (14-55) 32 (20-46) 58 (44-71) 43 (35-52) Median response duration, wk (range) NR (9+ – 60+) NR (11 – 72+) NR (8+ – 76+) NR (8+ – 76+) NR (9 – 60+) NR (11 – 65+) NR (12 – 93+) NR (9 – 93+) Median PFS, wk (95% CI) 72 (12-NR) 24 (12-36) 50 (24-NR) 31 (19-50) 72 (12-NR) 30 (15-NR) 84 (24-NR) 54 (24-NR) 24-wk PFS, % 56 44 60 53 51 54 64 58

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2014.32.15_suppl.3005

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 89

Metadata

Authors
Kefford, R., Ribas, A., Hamid, O., Robert, C., Daud, A., Wolchok, J. D., Joshua, A. M., Hodi, F. S., Gangadhar, T. C., Hersey, P., Weber, J. S., Dronca, R. S., Patnaik, A., Zarour, H. M., Dolled-Filhart, M., Lunceford, J., Emancipator, K., Ebbinghaus, S., Kang, S. P., & Hwu, W.-J.
Venue
Journal of Clinical Oncology
Published
2014-05-20
Volume
32
Issue
15_suppl
Pages
3005-3005
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2908271323
Cited by
89
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. https://app.cochat.ai/papers/10.1200/jco.2014.32.15_suppl.3005
The paper
Kefford, R., Ribas, A., Hamid, O., Robert, C., Daud, A., Wolchok, J. D., Joshua, A. M., Hodi, F. S., Gangadhar, T. C., Hersey, P., Weber, J. S., Dronca, R. S., Patnaik, A., Zarour, H. M., Dolled-Filhart, M., Lunceford, J., Emancipator, K., Ebbinghaus, S., Kang, S. P., & Hwu, W.-J. (2014). Clinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2014.32.15_suppl.3005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.